Skip to main content
Last Updated
Case Status
Pending
Federal Trade Commission and State of New York, Plaintiffs v. Vyera Pharmaceuticals, LLC, a Delaware limited liability corporation; Phoenixus AG, a Swiss for-profit corporation; Martin Shkreli, individually, as an owner and former director of Phoenixus AG, and as a former executive of Vyera Pharmaceuticals, LLC; and Kevin Mulleady, individually, as an owner and director of Phoenixus AG, and as a former executive of Vyera Pharmaceuticals, LLC; Defendants.
FTC Matter/File Number
161 0001
Civil Action Number
20-cv-00706
Federal Court
Southern District of New York

Case Summary

The Federal Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote banned Shkreli for life from the pharmaceutical industry.